WO2003013549A2 - Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern - Google Patents
Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblüternInfo
- Publication number
- WO2003013549A2 WO2003013549A2 PCT/EP2002/008940 EP0208940W WO03013549A2 WO 2003013549 A2 WO2003013549 A2 WO 2003013549A2 EP 0208940 W EP0208940 W EP 0208940W WO 03013549 A2 WO03013549 A2 WO 03013549A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphatidylserine
- formulation
- formulation according
- creatine
- stress
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a formulation containing phosphatidylserine (PS) and / or lysophosphatidylserine for the prevention and treatment of stressful conditions in warm-blooded animals.
- PS phosphatidylserine
- lysophosphatidylserine for the prevention and treatment of stressful conditions in warm-blooded animals.
- Stress is a condition of the organism that is characterized by a specific syndrome (increased sympathetic activity, increased release of catecholamines, increased blood pressure, etc.) and by various non-specific stimuli (infections, injuries, burns, exposure to radiation, but also anger, joy, Performance pressure and other factors) can be triggered. Stress can also be understood as external influences to which the body is not adequately adapted, e.g. Operations, poisoning, pregnancy (Anon, Pschyrembel - Klinisches Wörterbuch, 1 990, Walter de Gruyter, Berlin-New York (1 990)).
- Stress can generally be described as environmental processes that trigger processes in the body via perceptual impulses, whereby eustress is understood to mean stimulating influences with a positive effect and distress-destroying influences with a negative effect.
- cortisone is formed in the adrenal glands, two hormonal glands that are slightly above the kidneys, but perform completely different tasks than the kidneys. Cortisone is one of the most important hormones in the body and its absence is fatal within a short period of time.
- the main effects of cortisone are:
- cortisone is precisely controlled by the body to enable it to be produced as required.
- the pituitary gland plays a crucial role here, which is a bean-sized structure below the cerebrum and approx. 6 cm behind the eyes. This is where the control hormone (control messenger) ACTH is formed, which induces the release of cortisone via the bloodstream in the adrenal glands.
- control hormone control messenger
- cortisone-containing medications for inflammatory diseases such as rheumatoid arthritis or bronchial asthma is a common cause. In these cases, it is an unavoidable medication side effect that disappears after the medication is stopped.
- Cushing's syndrome is caused by long-term and excessive formation of the hormone cortisone, the consequences of which were first described as a disease in 1 909 by the doctor Harvey Cushing. 70% of all cases of Cushing's syndrome are caused by benign tumors (adenomas) of the pituitary gland that produce too much ACTH.
- Cushing's syndrome This form of Cushing's syndrome is also known as central Cushing's syndrome or Cushing's disease (Cushing's disease) and affects women 5 times more often than men.
- Cushing's disease Cushing's disease
- these tumors which can also be malignant, are found in the lungs, but they can also be located in the thyroid, thymus or pancreas.
- benign or malignant adrenal tumors lead to Cushing's syndrome due to the excessive formation of cortisone.
- diabetes mellitus can also trigger diabetes mellitus.
- a study showed that over 2200 patients between 50 and 74 years old were newly diagnosed with diabetes mellitus within three years, with a dependency on the number of stress experiences that was not related to work-related stress, but to serious life events past five years. This relationship remained demonstrable even when family influences, alcohol consumption and physical activities were taken into account.
- the stimulus processing takes place in very specific areas in the brain.
- the cerebellum is responsible for the correct sequence of all body movements and also enables orientation in space.
- the cerebellum is located between the cerebellum and cerebrum and controls vital vegetative functions such as heat, water and energy balance.
- the forehead is obviously of particular importance for the development of consciousness, in which human beings differ from most other living things.
- Phospholipids play an extremely important role in connection with the function of cell membranes, in whose construction they are approximately 75% involved, whereby they ensure, among other things, the intercellular exchange of information by means of neurotransmitters.
- the group of phospholipids is composed of sphingolipids and phosphoglycerides, an important representative of the latter being phosphatidylserine.
- Phosphatidylserine occurs in naturally elevated concentrations in the brain, where it positively influences the extremely sensitive functions of the nerve cells and the cells connected to them.
- phosphatidylserine like the rest of the other phospholipids, not only has a beneficial direct effect on health. Phosphatidylserine can also improve the absorption of numerous other nutrients or dietary supplements or work together with these to work synergistically. This has been demonstrated in numerous double-blind clinical studies.
- Phosphatidylserine is also known to help the brain generate energy, to have a beneficial effect on the cell / cell connections (synapses), to enhance the action of chemical transmitter substances such as acetylcholine, dopamine and noradrenaline and serotonin, which improves cognitive abilities of the brain, such as concentration, learning ability, short-term memory and word memories, and thus counteracts the natural loss of brain performance in old age.
- WO 99/371 55 describes the use of combinations of tyrosine, methylating agents, phospholipids such as. B. phosphatidylserine, fatty acids and active substances of evening primrose in mental disorders.
- the effect is aimed at strengthening the central nervous system (CNS), whereby anorexia-related neurochemical deficits in the form of a premature deactivation of neurotransmitters in the CNS are remedied by increasing the dopamine and serotonin levels should be.
- the claimed effect is exemplified in older, human subjects between 48 and 65 years of age.
- Therapeutic also indicates central nervous dysfunction.
- PS can be used as a so-called “cerebration improver", that is, to improve mental reflection and memory performance in dementia and Parkinson's disease.
- phosphatidylserine as a therapeutic or dietary supplement is well known. Its effect in connection with disorders in the area of the CNS and here only in older people and the intake of PS from cattle brain in connection with stress studies in the sports area is also described. So far, no improvements have been observed with PS supplementation in people under the age of 40 and in people whose brain function corresponds to their average age.
- F. Drago et al. describes the protective effect of phosphatidylserine in stress-induced behavior in old rats (Neurobiology of Aging 1 2 (5), 437-440, 1 991), which is said to have shown in particular in a normalization of body temperature.
- a positive effect of phosphatidylserine is also said to have been shown in gastric wall lesions, but this is only proven for older rats; this effect was not observed in young rats.
- bovine brain phosphatidylserine was only commercially extractable from bovine brain. Administered in large quantities (800 mg per day), it was shown that bovine brain phosphatidylserine, administered orally, could reduce the increase in cortisone and ACTH in the case of physical stress induced by intensive cycling training (P. Monteleone et al., Blunting by chronic phosphatidylserine administration of stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men, Eur. J. Clin. Pharmacol., 42, 385-388, 1 992; P. Monteleone et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans, Neuroendocrinology, 52, 243-248, 1 990).
- Extracts and extracts of plant origin are known from numerous publications and preparations known on the market, which are intended to alleviate or even prevent typical stress symptoms.
- the best known in this context are gingko biloba, kava kava, St. John's wort and ginseng.
- Extracts from Rhodiola rosea a well-known plant of traditional medicine in Eastern Europe and Asia, are also known, which are said to have an effect on the nervous system, an antidepressant activity and an improvement in physical performance.
- Rhodiola rosea has been studied in particular by Russian researchers who attribute an adaptogenic effect to it.
- Ginseng species and here in particular the so-called American, Siberian, Korean and Manchurian ginseng species which are among the oldest medicinal plants, are believed to reduce stress.
- Schisandra species whose common name is Wu-Wei-Zi (Schisandra chinensis) mostly occurs as a woody vine plant in northern and northeastern China and the adjacent regions of Russia and Korea.
- the full ripe and sun-dried red berries are used medicinally for relaxation symptoms, hepatitis, infectious diseases, for liver support, but also for stress symptoms.
- Suma or Para toda which is the dried root of Pfaffia panicolata, a plant that occurs in the Atlantic rainforest area of Brazil, has also been found to have numerous active components.
- This South American plant known as "Brazilian ginseng” is also attributed to the adaptogens because it can strengthen the immune system and can have positive effects in pain and chronic fatigue syndromes. In addition, this plant is said to have an accelerating effect in wound healing.
- the object of the present invention is therefore to provide a formulation which can be used in a well-dosed manner in stressful conditions in warm-blooded animals or for their prevention, shows good resorbability and has no negative side effects and is based on the known action of phosphatidylserine.
- phosphatidylserines e.g. Phosphatidyl-L-serine or lyso-phosphatidyl-L-serine
- physiologically compatible salts e.g. Phosphates and (earth) alkali compounds, which are abbreviated in this context as phosphatidylserine or PS.
- All other phospholipids mentioned also fall within this definition.
- the proportion of PS to other active component is preferably 99: 1 to 1:99% by weight /% by weight, more preferably 95: 5 to 5:95% by weight /% by weight and most preferably 90 : 10 to 1 0:90 wt% / wt%.
- PS in particular has a particularly good positive effect if it is obtained from plant sources, preferably soya, but also from milk or eggs; lecithin-containing oils from rapeseed and sunflowers are also suitable as vegetable sources.
- the transphosphatidylation is generally carried out on lecithins, such as those found in the vegetable oils mentioned, for example in rapeseed, soya and sunflower, but also in eggs.
- PS from non-bovine brain sources is preferably used.
- starting material is therefore not only to be understood in the sense that it actually contains phosphatidylserine, but also that the starting material contains substances such as e.g. Contains lecithins from which PS is obtained enzymatically or synthetically.
- the phosphatidylserine is administered in daily doses of 50 to 1000 mg, with 200 to 600 mg being preferred.
- the respective daily amount is of course especially in children and adolescents to their body indices, such as height and weight, and not least depending on whether PS is used for prophylaxis or for acute treatment.
- the claimed formulation in addition to the components (lyso) phosphatidylserine essential to the invention and the further active components, further components with stress-preventing / reducing effects such as creatine and its suitable derivatives, vitamins of the B series, which are different from creatine citrate and pyruvate and C as well as docosahexaenoic acid and mixtures thereof.
- the optional creatine component can be present as creatine monohydrate, another creatine salt, a creatine-containing compound or mixtures thereof in the claimed formulation, with the further component generally preferably in amounts of from 1.0 to 99.0% by weight. -% should be included based on the total formulation.
- the aggregate state of the claimed formulation is also not restricted within wide limits, but the solid and liquid form are to be regarded as preferred.
- Neurotransmitters, stimulants, blood circulation-promoting compounds and (plant) extracts have been found to be very suitable, with, of course, preferably also additive- or synergistic combinations of
- Phosphatidylserine with the compounds and / or medications known to date or other suitable for the treatment of mental distress, but preferably medicaments which inhibit cortisol formation in the adrenal glands, are suitable.
- the present invention provides carbohydrates (for example methyl cellulose), SiO 2 , stearates, solubilizers, colorants and flavorings, preservatives and release agents and texturants as particularly suitable formulation auxiliaries.
- the present invention also relates to its use, in particular in the case of mental distress and here preferably in the case of disorders of the ability to concentrate, disorders of the memory, disorders of the memory, disorders of the ability to learn, with reduced mental receptivity, reduced brain perfusion, mental fatigue, mental exhaustion, in the event of anxiety and symptoms, a disturbed ACTH (adrenocorticotropic hormone) household, e.g. Cushing syndrome as well as mental stress in the context of sporting activities such as Golf, biathlon and chess.
- ACTH adrenocorticotropic hormone
- the use of the claimed formulation for typical symptoms of physical distress such as Muscle twitching, nerve and headache, disorders of physical performance, circulatory disorders, reduced digestive processes, impaired sexual function, disorders of the immune system, impaired wound healing, symptoms of disturbed ACTH (adrenocorticotropic hormone) balance and physical stress in the context of sporting activities, such as e.g. Golf, claimed.
- phosphatidylserine as the body's own substance, is usually metabolized very quickly and completely and therefore has its good effect after only a short “flood time”. Nevertheless, a minimum period of use of one week should be provided for stress-related applications. According to the invention, a maximum of 6 months is to be observed as the upper limit for the regular intake of phosphatidylserine in stress-related applications, but the Supplementation periods after breaks and / or readjustment of the daily dose can be repeated several times without any problems whatsoever.
- phosphatidylserine-containing combination formulations for the prophylaxis and treatment of mental and / or physical stress conditions, who are between the ages of 10 and 50 and preferably between the ages of 20 and 35 years moved.
- the formulation according to the invention can also be used at any other age in connection with stress symptoms.
- the formulation containing PS and other active components is very well suited in the context of the present invention, in particular as a therapeutic agent and / or nutritional supplement, the dosage being kept low and the administration especially in the latter case can also take place over longer periods of time, which is particularly important in connection with targeted stress prophylaxis.
- the present invention also provides for the use of the formulation in functional foods and / or as part of a special nutrition (clinical nutrition).
- solid formulations in particular powder, chewable, lozenge and effervescent tablets, dragees and capsules and, considering the mostly small age of the preferred subjects, candy are possible.
- liquid formulations juices and soft drinks have proven to be particularly suitable in connection with compliance.
- the present invention relates to a formulation containing phosphatidylserine (PS) and / or lysophosphatidylserine for the prevention and treatment of mental and physical stress conditions, the phosphatidylserine and others. is combined with herbal extracts or extracts.
- PS phosphatidylserine
- herbal extracts or extracts are combined with herbal extracts or extracts.
- daily doses of 50 to 1,000 mg PS are provided, which should be administered over a maximum period of six months. People between the ages of 10 and 50 are considered as preferred test subjects.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02754989A EP1414469A2 (de) | 2001-08-09 | 2002-08-09 | Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern |
KR1020047001781A KR100680121B1 (ko) | 2001-08-09 | 2002-08-09 | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 |
BR0211814-9A BR0211814A (pt) | 2001-08-09 | 2002-08-09 | Formulação contendo (liso-)fosfatidilserina para a prevenção e tratamento de estados de tensão em animais de sangue quente |
JP2003518556A JP2004537577A (ja) | 2001-08-09 | 2002-08-09 | 温血動物のストレス状態の予防用及び治療用の(リゾ)ホスファチジルセリン含有製剤 |
NZ530981A NZ530981A (en) | 2001-08-09 | 2002-08-09 | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
US10/486,314 US20040234544A1 (en) | 2001-08-09 | 2002-08-09 | Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10139250.8 | 2001-08-09 | ||
DE10139250A DE10139250A1 (de) | 2001-08-09 | 2001-08-09 | Verwendung von Phosphatidylserin und/oder lyso-Phosphatidylserin aus Nicht-Rinderhirnquellen und/oder deren physiologisch verträglicher Salze bei Warmblütern |
DE10235760.9 | 2002-08-05 | ||
DE10235760A DE10235760A1 (de) | 2001-08-09 | 2002-08-05 | Formulierung enthaltend (lyso-)Phosphatidylserin zur Vorbeugung und Behandlung von Stresszuständen bei Warmblütern |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003013549A2 true WO2003013549A2 (de) | 2003-02-20 |
WO2003013549A3 WO2003013549A3 (de) | 2003-11-06 |
Family
ID=26009917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008940 WO2003013549A2 (de) | 2001-08-09 | 2002-08-09 | Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040234544A1 (de) |
EP (1) | EP1414469A2 (de) |
JP (1) | JP2004537577A (de) |
KR (1) | KR100680121B1 (de) |
CN (1) | CN1625406A (de) |
BR (1) | BR0211814A (de) |
NZ (1) | NZ530981A (de) |
WO (1) | WO2003013549A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307425A (ja) * | 2003-04-10 | 2004-11-04 | Nonogawa Shoji Kk | 抗ストレス剤 |
EP1559430A1 (de) * | 2004-01-29 | 2005-08-03 | INDENA S.p.A. | Verwendung von Ginkgokomplexen zur Verbesserung von kognitiven Leistungen und Linderung der mentalen Ermüdung |
JP2005247841A (ja) * | 2004-02-04 | 2005-09-15 | Fancl Corp | 抗不安剤 |
WO2005094855A1 (de) * | 2004-03-25 | 2005-10-13 | Bionorica Ag | Salix spec. (weide) extrakt enthaltende pharmazeutische zusammensetzung zur behandlung von depressionen, schlafstörungen, angst-und/oder unruhezuständen |
EP1605764A2 (de) * | 2003-03-14 | 2005-12-21 | Pro-Health, Inc. | Zusammensetzung und verfahren für die appetitzügelung, unterdrückung von heisshunger und stimmungsaufhellung |
WO2018108238A1 (fr) * | 2016-12-12 | 2018-06-21 | Urgo Recherche Innovation Et Developpement | Produit de combinaison pour aider à la relaxation et à l'endormissement |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7033612B2 (en) * | 2003-01-03 | 2006-04-25 | Kang David S | Composition and method for treating age-related disorders |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8231913B2 (en) * | 2005-11-10 | 2012-07-31 | Jose Angel Olalde Rangel | Angina pectoris and ischemic heart disease and synergistic phytoceutical composition for same |
US7303772B2 (en) * | 2005-11-10 | 2007-12-04 | Olalde Rangel Jose Angel | Synergistic phytoceutical compositions |
AU2006338839A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
EP2486919A1 (de) | 2006-04-19 | 2012-08-15 | Jianxun Liu | Chinesische Medizinzusammensetzung und Zubereitungsverfahren und ihre Verwendung |
US20080031978A1 (en) * | 2006-04-20 | 2008-02-07 | Chou Wen H | Compositions and methods for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
US20070292536A1 (en) * | 2006-06-16 | 2007-12-20 | Gottfried Kellermann | Composition and method for treating patients with high neurotransmitter levels |
JP2008214338A (ja) * | 2007-02-08 | 2008-09-18 | Shiseido Co Ltd | 高次脳機能低下改善剤および遅延記憶低下改善剤 |
US8124594B2 (en) * | 2007-11-30 | 2012-02-28 | Chemi Nutra, Llc | Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels |
JP2009196948A (ja) * | 2008-02-22 | 2009-09-03 | Fancl Corp | 疲労感低減剤 |
US7906159B2 (en) * | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
CN101336678B (zh) * | 2008-08-08 | 2011-02-16 | 武汉明天生物科技有限公司 | 提高猪的生长速度、改善猪肉品质的预混合饲料 |
CN101982121B (zh) * | 2010-09-19 | 2012-09-05 | 中国科学院广州生物医药与健康研究院 | 一种功能性运动饮料及其制备方法 |
WO2015054694A2 (en) | 2013-10-13 | 2015-04-16 | 4Life Patents, Llc | Therapeutic compositions and methods for addressing physiological stresses and aging |
WO2015069870A1 (en) * | 2013-11-07 | 2015-05-14 | The University Of North Carolina At Chapel Hill | Particles containing phospholipids or bioactive fatty acid |
CN105726744A (zh) * | 2016-04-07 | 2016-07-06 | 沙海涛 | 一种包含五味子和磷脂酰丝氨酸的药物及其制备方法 |
CN105816705A (zh) * | 2016-04-07 | 2016-08-03 | 赵卫军 | 一种包含玉米须和磷脂酰丝氨酸的药物及其制备方法 |
CN105726612A (zh) * | 2016-04-08 | 2016-07-06 | 洪海波 | 一种包含红景天和磷脂酰丝氨酸的药物及其制备方法 |
CN106539084A (zh) * | 2016-11-11 | 2017-03-29 | 延边韩工坊健康制品有限公司 | 一种改善记忆力保健食品及其制备方法 |
CN108095123A (zh) * | 2017-12-19 | 2018-06-01 | 北京特食生物科技研究中心(有限合伙) | 一种缓解压力的营养组合物及其制备方法与应用 |
CN112956649A (zh) * | 2021-03-25 | 2021-06-15 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 防治老年痴呆复合制剂及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148045A1 (de) * | 1983-11-17 | 1985-07-10 | FIDIA S.p.A. | Pharmazeutische Zusammensetzungen und Verfahren für die Herstellung von Zusammensetzungen mit Gehalt an Phosphatidylserine zur Behandlung von Störungen des centralen Nervensystems ohne Wirkungen auf die Blutkoagulation |
JPH02265457A (ja) * | 1989-04-04 | 1990-10-30 | Nikken Food Kk | 頭脳栄養補助食品 |
EP0711559A2 (de) * | 1994-11-08 | 1996-05-15 | Kabushiki Kaisha Yakult Honsha | Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserungen der Gehirntätigkeit |
WO1998004253A1 (en) * | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
WO1999037155A1 (en) * | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
FR2775600A1 (fr) * | 1998-03-05 | 1999-09-10 | Ravi Shrivastava | Nouvelle composition pharmaceutique pour le traitement des troubles d'origine neurologique |
WO2001003325A2 (de) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen |
WO2001026646A1 (en) * | 1999-10-08 | 2001-04-19 | Pharmnseas, Inc. | NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0311827A (ja) * | 1989-06-09 | 1991-01-21 | Nec Corp | 誤り検出訂正回路 |
RU2045275C1 (ru) * | 1992-05-08 | 1995-10-10 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Витаминный чайный сбор "мятный" из лекарственных растений |
JP3318412B2 (ja) * | 1993-10-29 | 2002-08-26 | 日清フーズ株式会社 | α波増強剤 |
JPH09227394A (ja) * | 1995-12-22 | 1997-09-02 | Taisho Pharmaceut Co Ltd | 経口投与用組成物 |
JPH1180009A (ja) * | 1997-09-12 | 1999-03-23 | Seiwa Yakuhin Kk | 脳機能の改善剤および低下予防剤 |
EP1047440A1 (de) * | 1998-01-13 | 2000-11-02 | Rexall Sundown, Inc. | Zusammensetzung auf basis von johanniskraut und methyldonoren sowie deren verwendungen |
JP2002510604A (ja) * | 1998-04-02 | 2002-04-09 | アビセナ グループ, インク. | クレアチン化合物及び第二物質の組み合わせを含む組成 |
CN1130994C (zh) * | 1998-04-21 | 2003-12-17 | 沈阳药科大学 | 红景天健身饮料 |
US6399116B1 (en) * | 2000-04-28 | 2002-06-04 | Rulin Xiu | Rhodiola and used thereof |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
-
2002
- 2002-08-09 WO PCT/EP2002/008940 patent/WO2003013549A2/de active Application Filing
- 2002-08-09 CN CNA028169611A patent/CN1625406A/zh active Pending
- 2002-08-09 NZ NZ530981A patent/NZ530981A/en unknown
- 2002-08-09 KR KR1020047001781A patent/KR100680121B1/ko not_active IP Right Cessation
- 2002-08-09 JP JP2003518556A patent/JP2004537577A/ja active Pending
- 2002-08-09 US US10/486,314 patent/US20040234544A1/en not_active Abandoned
- 2002-08-09 EP EP02754989A patent/EP1414469A2/de not_active Withdrawn
- 2002-08-09 BR BR0211814-9A patent/BR0211814A/pt not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148045A1 (de) * | 1983-11-17 | 1985-07-10 | FIDIA S.p.A. | Pharmazeutische Zusammensetzungen und Verfahren für die Herstellung von Zusammensetzungen mit Gehalt an Phosphatidylserine zur Behandlung von Störungen des centralen Nervensystems ohne Wirkungen auf die Blutkoagulation |
JPH02265457A (ja) * | 1989-04-04 | 1990-10-30 | Nikken Food Kk | 頭脳栄養補助食品 |
EP0711559A2 (de) * | 1994-11-08 | 1996-05-15 | Kabushiki Kaisha Yakult Honsha | Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserungen der Gehirntätigkeit |
WO1998004253A1 (en) * | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
WO1999037155A1 (en) * | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
FR2775600A1 (fr) * | 1998-03-05 | 1999-09-10 | Ravi Shrivastava | Nouvelle composition pharmaceutique pour le traitement des troubles d'origine neurologique |
WO2001003325A2 (de) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen |
WO2001026646A1 (en) * | 1999-10-08 | 2001-04-19 | Pharmnseas, Inc. | NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Non-Patent Citations (9)
Title |
---|
BENTON D. ET AL.: "The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor." NUTR. NEUROSCIENCE., Bd. 4, 2001, Seiten 169-178, XP001119807 * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1995-063782 XP002222606 & JP 03 011827 A (KATSUNARI S.K.K.), 21. Februar 2000 (2000-02-21) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1995-212887 XP002222611 & JP 07 126179 A (NISSHING FLOUR MILLING CO.), 16. Mai 1995 (1995-05-16) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1996-237622 XP002222608 & RU 2 045 275 A (A MED. TOMSK PHARMACOL. RES. INST.), 10. Oktober 1995 (1995-10-10) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1997-539684 XP002222610 & JP 09 227394 A (TAISHO PHARM. CO.), 2. September 1997 (1997-09-02) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1999-444320 XP002222609 & WO 99 36080 A (REXALL SUNDOWN INC.), 22. Juli 1999 (1999-07-22) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 2000-106919 XP002222607 & CN 1 232 649 A (UNIV. SHENYANG), 27. Oktober 1999 (1999-10-27) * |
MONTELEONE P. ET AL.: "Blunting by chronic phosphatidylserine administration of stress-induced activation of the hypothalamic-pituitary-adrenal axis in healthy men." EUR. J. CLIN. PHARMACOL., Bd. 42, Nr. 4, 1992, Seiten 385-388, XP001119805 * |
PATENT ABSTRACTS OF JAPAN vol. 015, no. 027 (C-0797), 22. Januar 1991 (1991-01-22) & JP 02 265457 A (NIKKEN FOOD KK), 30. Oktober 1990 (1990-10-30) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1605764A2 (de) * | 2003-03-14 | 2005-12-21 | Pro-Health, Inc. | Zusammensetzung und verfahren für die appetitzügelung, unterdrückung von heisshunger und stimmungsaufhellung |
EP1605764A4 (de) * | 2003-03-14 | 2008-07-23 | Eurark Llc | Zusammensetzung und verfahren für die appetitzügelung, unterdrückung von heisshunger und stimmungsaufhellung |
JP2004307425A (ja) * | 2003-04-10 | 2004-11-04 | Nonogawa Shoji Kk | 抗ストレス剤 |
EP1559430A1 (de) * | 2004-01-29 | 2005-08-03 | INDENA S.p.A. | Verwendung von Ginkgokomplexen zur Verbesserung von kognitiven Leistungen und Linderung der mentalen Ermüdung |
WO2005074956A1 (en) * | 2004-01-29 | 2005-08-18 | Indena S.P.A. | Use of a ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue |
AU2005210091B2 (en) * | 2004-01-29 | 2010-06-03 | Indena S.P.A. | Use of a Ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue |
US8591965B2 (en) | 2004-01-29 | 2013-11-26 | Indena S.P.A. | Use of a ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue |
JP2005247841A (ja) * | 2004-02-04 | 2005-09-15 | Fancl Corp | 抗不安剤 |
WO2005094855A1 (de) * | 2004-03-25 | 2005-10-13 | Bionorica Ag | Salix spec. (weide) extrakt enthaltende pharmazeutische zusammensetzung zur behandlung von depressionen, schlafstörungen, angst-und/oder unruhezuständen |
WO2018108238A1 (fr) * | 2016-12-12 | 2018-06-21 | Urgo Recherche Innovation Et Developpement | Produit de combinaison pour aider à la relaxation et à l'endormissement |
Also Published As
Publication number | Publication date |
---|---|
BR0211814A (pt) | 2004-09-08 |
EP1414469A2 (de) | 2004-05-06 |
JP2004537577A (ja) | 2004-12-16 |
KR100680121B1 (ko) | 2007-02-07 |
CN1625406A (zh) | 2005-06-08 |
US20040234544A1 (en) | 2004-11-25 |
WO2003013549A3 (de) | 2003-11-06 |
NZ530981A (en) | 2006-06-30 |
KR20040019382A (ko) | 2004-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003013549A2 (de) | Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern | |
DE602004012745T2 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
US20230072854A1 (en) | Paraxanthine-based bioactive composition and method of use thereof | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
EP1435971B1 (de) | Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs) | |
RU2449600C1 (ru) | Биологически активная пищевая добавка | |
EP2608798B2 (de) | Pflanzenextrakte aus gliedkräutern und deren verwendung zur steigerung kognitiver leistungsfähigkeit | |
DE202023001867U1 (de) | Formulierung umfassend mindestens eine Kresse-Art | |
DE60124516T3 (de) | Kombination des lezithins mit ascorbinsäure | |
US10583095B2 (en) | Method for stress management and overall health status improvement and compositions used therein | |
EP3111930B1 (de) | Zusammensetzung zur behandlung von depressionen, bipolaren störungen, rezidivierenden depressiven störungen und anderen anhaltenden affektiven störungen | |
US11376294B2 (en) | Mangiferin-containing compositions for improving sports performance | |
DE10235760A1 (de) | Formulierung enthaltend (lyso-)Phosphatidylserin zur Vorbeugung und Behandlung von Stresszuständen bei Warmblütern | |
US20150086660A1 (en) | Compositions Containing Myristica fragrans | |
AT17577U1 (de) | Nahrungsergänzungsmittel mit Haferkrautextrakt | |
EP2548564B1 (de) | Pharmazeutisches Mittel, Ernährung für einen Patienten sowie Verfahren zur Gewichtsreduzierung | |
Katekar et al. | A review: Ethanopharmacolical review of native traditional medicinal plants as a memory booster | |
EP1161252B1 (de) | Verwendung von extrakten aus ginkgo-biloba-blättern zur behandlung von schlafstörungen | |
DE102020130273A1 (de) | Wirkstoff-Zusammensetzung | |
Tusaie | Overview of complementary/Alternative approaches | |
EP1563743B1 (de) | Mischung enthaltend eine koffeinhaltige Substanz, insbesondere Guarana | |
EP2796143A1 (de) | Pharmazeutisches homöopathisches Arzneimittel zur Gewichtsreduktion | |
DE102012002428A1 (de) | Therapie-Infusionslösung, insbesondere Makula-Degeneration-Therapie-Infusionslösung oder Polyneuropathie-Therapie-Infusionslösung oder Parkinson-Therapie-Infusionslösung oder Multiple-Sklerose-Therapie-Infusionslösung oder Demenz-Therapie-Infusionslösung | |
Tripathi | Herbal memory enhancer: A review | |
Soldati | Ginseng, Asian (Panax ginseng) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002754989 Country of ref document: EP Ref document number: 2004/00830 Country of ref document: ZA Ref document number: 2002321300 Country of ref document: AU Ref document number: 200400830 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003518556 Country of ref document: JP Ref document number: 530981 Country of ref document: NZ Ref document number: 1020047001781 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10486314 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028169611 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002754989 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |